# A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

> **NCT04740918** · PHASE3 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 96 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab Emtansine
- **DRUG:** Atezolizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04740918
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-07
- **Primary completion:** 2024-06-19
- **Final completion:** 2024-06-19
- **Target enrollment:** 96 (ACTUAL)
- **Why stopped:** Due to low enrollment, the Sponsor decided to prematurely terminate the study
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740918, "A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04740918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*